EW
ALXN

Evoke Wealth’s Alexion Pharmaceuticals ALXN Stock Holding History

Evoke Wealth’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-88
Closed -$16K – 1247
2021
Q2 		$16K Sell
88
-4
-4% -$687 ﹤0.01% 689
2021
Q1 		$14K Hold
92
– – ﹤0.01% 642
2020
Q4 		$14K Buy
92
+4
+5% +$514 ﹤0.01% 538
2020
Q3 		$10K Hold
88
– – ﹤0.01% 571
2020
Q2 		$10K Sell
88
-8
-8% -$849 ﹤0.01% 557
2020
Q1 		$8.62K Sell
96
-46
-32% -$4.51K ﹤0.01% 524
2019
Q4 		$15.4K Buy
142
+38
+37% +$4.06K ﹤0.01% 652
2019
Q3 		$10.2K Buy
+104
New +$11.7K ﹤0.01% 815

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $11.7B AUM 21.33% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $379M AUM 28.34% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $280B AUM 33.63% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return